

Table 1 (online suppl.). Type of stroke and antiplatelet treatment in patients under follow-up.

	Total		LI		TIA	
	TF	ASA	TF	ASA	TF	ASA
Rev Neurol 1997 [5]	106	111	20	20	-	-
Rev Neurol 1996 [12]	135	-	28	-	28	-
TACIP [6]	47	42	20	19	8	7
	288	153				

TF = Triflusal

ASA= aspirin

LI= lacunar infarction

TIA= transient ischemic attack

Table 2 (online suppl.). Global descriptive analysis comparing previous studies of ASA vs. triflusal [6,7] with the HUVH study.

Trial	Number of cases	Triflusal/ aspirin	Mean (min-max) follow-up , years	Mean age	Gender, male	T.I.A	Lacunar stroke
TACIP	2107	1055/1052	2.5 (0-3)	64.5	65.8%	26.0%	52.0%
TAPIRSS	427	211/216	1.6 (0-2)	64.7	68.3%	19.2%	41.3%
HUVH	441	288/153	17.2 (0-27)	51.1	69.2%	9.8%	24.3%

Table 3 (online suppl.). New vascular events and adverse events in previous studies of ASA vs. triflusal [6,7] and in the HUVH study.

Trial	Annual event rate, %/year		Major systemic hemorrhages	Gastrointestinal event	HDA	Cerebral hemorrhage	Other hemorrhages
	Recurrent stroke	Vascular event					
TACIP	4.06%	4.93%	2.94%	60.37%	6.12%	0.66%	12.91%
TAPIRSS	4.19%	6.98%	1.87%	37.47%	2.58%	0.70%	2.34%
HUVH	2.20%	2.97%	9.07%	53.51%	6.58%	3.40%	10.66%